The Centers for Disease Control and Prevention on Wednesday recommended Novavax‘s Covid boosters for adults in the U.S., including for people who received Pfizer, Moderna or Johnson & Johnson’s shots as their primary series.
The Food and Drug Administration, in a factsheet for healthcare providers, said adults ages 18 and older can receive Novavax as their third dose six months after completion of the primary series of a U.S. authorized Covid vaccine.
The CDC gave the final go ahead for pharmacies to start administering the Novavax boosters just hours after the FDA had authorized the shots. Dr. Evelyn Twentyman, a CDC official, announced the Novavax recommendation during a meeting of the agency’s independent vaccine experts Wednesday afternoon.
The CDC recommended Novavax’s boosters without a debate or vote from its independent experts.
The authorization of Novavax’s booster could significantly increase the role that its shot plays in U.S. vaccination efforts. Up until now, Novavax’s vaccine was only authorized as a two-dose primary series, which limited its market because so many people were already immunized with Pfizer or Moderna. Tens of thousands of people have been immunized against Covid with Novavax’s shots compared with more than 200 million who’ve received other vaccines in the U.S.
The company’s shares jumped by almost 6% in morning trading but were flat by noon.
The FDA’s decision to allow people who received two doses of Pfizer or Moderna to receive Novavax as their third shot means millions of more people can get the Maryland biotech company’s vaccine.
“According to CDC data, almost 50 percent of adults who received their primary series have yet to receive their first booster dose. Offering another vaccine choice may help increase COVID-19 booster vaccination rates for these adults,” Novavax CEO Stanley Erck said in a statement Wednesday.
Only 35,300 people have received Novavax’s shots as a primary series so far in the U.S., according to data from the CDC. By comparison, some 372.5 million Pfizer shots, 235.8 million Moderna doses and 18.9 million Johnson & Johnson shots have been administered across the U.S. so far.
But allowing for mix and matching opens Novavax’s market up to roughly the 100 million adults in the US who have completed their primary series but not received a first booster dose.
The FDA’s authorization of Novavax’s boosters comes as millions of Americans have already received Pfizer’s and Moderna’s new bivalent shots that target the dominant omicron BA.5 subvariant and the original strain of Covid that first emerged in Wuhan, China in 2019.
U.S. health officials believe Pfizer and Moderna’s updated boosters will provide stronger protection against infection and disease this winter than the first generation of vaccines because they target omicron BA.5, which is causing most infections right now.
Novavax’s newly authorized booster was developed against the original strain of Covid but the company believes its protein technology provides durable protection across different variants of the virus. Novavax’s shots rely on more conventional technology used in other vaccines for decades rather than the newer messenger RNA platform used by Pfizer and Moderna.
Novavax said its booster doses triggered robust antibodies against omicron BA.1, BA.2 and the dominant BA.5 subvariant in studies that observed adults who received the third shot 8 to 11 months after receiving their Novavax primary series.
The booster dose also induced an immune response in participants who received Moderna, Pfizer and Johnson & Johnson as their primary series, according to the company.
Dr. Filip Dubovsky, Novavax’s chief medical officer, said the company believes its shots will provide durable protection even as the virus continues to evolve.
“We think we have a product that has a broad immune response, so we’re not going to be chasing the virus each time a new a new variant crops up. That needs to be proven but that’s our hypothesis,” Dubovsky said.
The most common side effects of Novavax’s vaccine are pain at the injection site, fatigue, headache, muscle pain, nausea and vomiting, according to the Centers for Disease Control and Prevention.
The FDA, in a fact sheet for health-care providers, has warned that Novavax’s primary series appears to carry a risk of heart inflammation called myocarditis. Pfizer’s and Moderna’s shots also carry an elevated risk of myocarditis primarily in young men and adolescent boys after the second dose.
A study from the CDC last spring found that Covid infection carries a higher risk of myocarditis than Pfizer or Moderna vaccination.
Novavax has not presented real-world efficacy data on how its shots perform against BA.5, one of the most immune evasive variants of Covid yet. Pfizer and Moderna also do not have real-world data on how their new boosters perform against BA.5.
Novavax was one of the original participants in the U.S. race to develop a vaccine in 2020 and received $1.8 billion in taxpayer money, but fell behind Pfizer and Moderna because it had difficulties getting its manufacturing in place.
The FDA authorized Novavax’s two-dose primary series over the summer in the hope that people who are skeptical of Pfizer’s and Moderna’s shots would be more willing to get immunized with the Novavax version. People ages 12 and older are eligible for Novavax’s primary series, while people 18 and over can now get its booster shot.
People who received Novavax’s vaccine as their primary series are also eligible for Pfizer and BioNTech’s or Moderna’s new omicron booster.
Correction: People who receive Novavax’s vaccine as a primary series are eligible for Pfizer or Moderna’s new omicron booster. A previous version of the story misstated the eligibility.